| 1 |
Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: world-wide incidence and trends [J]. Gastroenterology, 2004, 127(5Suppl 1):S5-S16.
|
| 2 |
GLOBOCAN 2008[OL]. [2013-10-29].
URL
|
| 3 |
Liu J, Yi J. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Huazhong Univ Sci Technolog Med Sci, 2007, 27(1):58-60.
|
| 4 |
Thomas MB,Chadha R,Glover K,et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma [J].Cancer, 2007, 110(5):1059-1067.
|
| 5 |
O’Dwyer PJ,Giantonio BJ,Levy DE,et al.Gefitinib in advanced unresectable hepatocelluar carcinoma:results from the Eastern Cooperative on cology Group’s Study E1203 (Meeting Abstracts) [J]. J Clin Oncol, 2006, 24:18S(abstract 4143).
|
| 6 |
Ramanathan RK,Belani CP,Singh DA,et al.A phaseⅡstudy of lapatinib inpatients with advanced biliary tree and hepatocellular cancer [J].Cancer Chemother Pharmacol, 2009,64(4):777-783.
|
| 7 |
Zhu AX,Stuart K,Blasskowsky LS,et al.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma [J].Cancer, 2007, 110(3):581-589.
|
| 8 |
Schwartz JD,Schwartz M,Lehrer D,et al.Bevacizumab in unresectable hepatocellular carcinoma(HCC)for patients without metastasis and without invasion of the portalvein [J]. J Clin Oncol, 2006, 24(18):213S-213S.
|
| 9 |
Siegel AB,Cohen EI,Ocean A,et al.Phase Ⅱtrial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma [J].J Clin Oncol, 2008, 26(18):2992-2998.
|
| 10 |
Boige V,Malka D,Bourredjem A,et al.Efficacy,safety,and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma [J].Oncologist, 2012, 17(8):1063-1072.
|
| 11 |
Gollob JA, Wilhelm S, Carter C，et a1． Role of Raf kinasein cancer：Therapeutic potential of targeting the Raf/MEK／ERK sign altransduction pathway[J].Semin Oncol，2006,33(4):392.
|
| 12 |
Liu L, Cao Y, Chen C, et a1．Sorafenib blocks the RAF／MEK/ERK pathway，inhibits tumor angiogenesis，and induces tumor cell apoptosisin hepatocellular carcinoma ModelPLC/PRF/5[J].Cancer Res，2006，66(24):1185.
|
| 13 |
Vogl TJ, Naguib NN, Nour-Eldin NE,et al. Review on transarterial chemoembolization in hepatocel-lular carcinoma: palliative, combined,neoadjuvant,bridging, and symptomatic indications[J]. Eur J Radiol,2009,72(3):505-516.
|
| 14 |
Sergio A, Cristofori C, Cardin R,et al. Transcatheter arterial chemoemboliza-tion (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness[J]. Am J Gastroenterol,2008,103(4):914-921.
|
| 15 |
陈自谦，杨利，杨熙章, 等. 肝癌介入治疗现状与进展[J]. 介入放射学杂志，2008，17(3)223-226.
|
| 16 |
Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxo-rubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2010,33(3):541-551.
|
| 17 |
Takayasu K, Arii S, Ikai I,et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology,2006,131(2):461-469.
|
| 18 |
Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics[J]. J Hepatol,2007, 46(3):474-481.
|
| 19 |
Tezuka M, Hayashi K, Kubota K, et al. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma[J]. Dig Dis Sci, 2007, 52(3):783-788.
|
| 20 |
Georgiades CS, Hong K, D'Angelo M, et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis[J]. J Vasc Interv Radiol,2005, 16(12):1653-1659.
|
| 21 |
王执民，曹玮. 介入性热化疗治疗肝癌的研究现状[J]. 中国微创外科杂志, 2007, 7(7):666-667.
|
| 22 |
张家兴，樊树峰，郑家平, 等. 肝癌的介入性热化疗:最佳灌注温度的探讨[J]. 介入放射学杂志，2004，13(5):450-452.
|
| 23 |
张宁宁，饶荣生，陆伟，等．HCC伴PVTT经肝动脉-门静脉联合化疗栓塞疗效观察[J].实用肿瘤杂志，2012，20(4):253-255.
|
| 24 |
钱骏，Vossoughi D，OppermannE，等．血管生成抑制剂烟曲霉素衍生物在介入治疗肝细胞癌实验中的应用[J].中华放射学杂志，2006，40(1):13-15.
|
| 25 |
Maataoui A, Qian J, Vossoughi D，et al．Transarterial chemoembolization alone and in combination with other therapies：acomparative study in an animal HCC model [J]．Eur Radiol，2005，15(1):127-133.
|
| 26 |
Zhu AX, Blaszkowsky LS, Ryan DP．Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma [J]．J Clin Oncol，2006，24(12):1898-1903.
|
| 27 |
陈逢生，崔彦芝，罗荣城，等．索拉非尼联合顺铂对肝癌HepG-2细胞的抑制作用[J]．南方医科大学学报，2008，28:1684-1687.
|
| 28 |
Richly H, Schuhheis B, Adamietz IA．Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma：results from aphase extension trial [J]．Eur J Cancer，2009，45(4):579-587.
|
| 29 |
Takimoto CH, Awada A．Safety and anti-tumor activity of sorafenib(Nexavar) in combination with other anti-cancer agents：a review of clinical trials [J]．Cancer Chemother Pharmacol，2008，61(4):535-548.
|
| 30 |
Davis CR. Interventional radiological treatment of hepatocellular carcinoma[J]. Cancer Control，2010，17(1):87-99.
|
| 31 |
Zhang L, Fan WJ, Huang JH, et al. Comprehensive sequential interventional therapy for hepatocellular carcinoma[J]. Chin Med J (Engl) ,2009, 122(19):2292-2298.
|